RENIN-ANGIOTENSIN PROFILE AND COMPARATIVE EFFECTIVENESS OF FIRST-LINE MEDICATIONS IN MONOTHERAPY OF ESSENTIAL ARTERIAL HYPERTENSION

The study investigated the rational antihypertensive therapy in 966 patients with essential arterial hypertension (AH) and various renin-angiotensin blood profiles. Mean age was 51,4±10,2 years, mean systolic blood pressure (SBP) – 193,3±7,4 mm Hg, and mean diastolic BP (DBP) – 113,3± 4,8 mm Hg. Plasma renin activity (PRA; normal levels 1,0-3,0 ng/ml/h) and plasma aldosterone concentration (PAC; normal levels 5-23 ng/dl) were measured by radio-immune methods. The normal ratio of PAC (ng/dl) to PRA (ng/ml/h) is 5-23. It was demonstrated that in patients with PRA<0,22 ng/ml/h, the main monotherapy medications were angiotensin II receptor antagonists (ARA) and angiotensin-converting enzyme inhibitors (ACEI). In patients with PRA 0,22-1,0 ng/ml/h and PAC: PRA ratio 5-23, the main monotherapy medications were calcium antagonists (CA) and hydrochlorothiazide; in patients with PAC: PRA ratio >< 0,22 ng/ml/h, the main monotherapy medications were angiotensin II receptor antagonists (ARA) and angiotensin-converting enzyme inhibitors (ACEI). In patients with PRA 0,22-1,0 ng/ml/h and PAC: PRA ratio 5-23, the main monotherapy medications were calcium antagonists (CA) and hydrochlorothiazide; in patients with PAC: PRA ratio >23 – ACEI and ARA; in patients with PRA 1,0-3,0 mg/ml/h and normoaldosteronism – CA; in patients with PRA >3,0 ng/ml/h and PAC: PRA ratio< 5 – beta-adrenoblockers.

1. Lewington S, Clarke R, Qizilbash N et al. For the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies//Lancet 2002; 360:1903-13.

2. Сollins R, Peto R, MacMahon S. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reduction of blood pressure// Lancet. 1990; 355;827-839.

3. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and risk of stroke and coronary disease//Br Med Bull 1994; 50:272-298.

4. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology; 2007 Guidelines for the management of arterial hypertension// J Hypertens 2007; 1105-87.

5. Chobanian AV, Bakris GL, Black H et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (complete version) // Hypertension 2003; 42: 1206-52.

6. Staessen JA, Li Y, Thijs L et al. Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials // Hypertens Res 2005; 28(5); 385- 407.

7. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review// JAMA, 1998;279;1303-1307.

8. Hanson L., Lindholm L.H., Niskanen L., et al. For the Captopril Prevention Project (CAPP) study group. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on carciovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial // Lancet 1999; 353: 611–6.

9. Dahlof B, Devereux RB, Kjeldsen SE et al. For LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet 2002; 359: 995–1003.

10. Staessen JA, Wang JG. Blood-pressure lowering for the secondary prevention of stroke // Lancet 2001; 358; 1026-1027.

11. Ахадов Ш.В, Рузбанова Г.Р, Молчанова Г.С, и др. Оценка активности и клиническое значение симпатоадреналовой системы у больных артериальной гипертензией//Российский кардиологический журнал. 2009, №2, стр.13-17.

12. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность АГ в России: информированность, лечение, контроль // Профилактика забол-й и укрепление здоровья. 2001, №2, 3-7.